Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. To discover such interactions, we developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a tool deconvolving cell type–specific gene expression in each sample from bulk expression, and LIRICS (Ligand–Receptor Interactions between Cell Subsets), a statistical framework prioritizing clinically relevant ligand–receptor interactions between cell types from the deconvolved data. We first demonstrate the superiority of CODEFACS versus the state-of-the-art deconvolution method CIBERSORTx. Second, analyzing The Cancer Genome Atlas, we uncover cell type–specific ligand–receptor interactions uniquely associated with mismatch-repair deficiency across different cancer types, providing additional insights into their enhanced sensitivity to anti–programmed cell death protein 1 (PD-1) therapy compared with other tumors with high neoantigen burden. Finally, we identify a subset of cell type–specific ligand–receptor interactions in the melanoma TME that stratify survival of patients receiving anti–PD-1 therapy better than some recently published bulk transcriptomics-based methods. Significance: This work presents two new computational methods that can deconvolve a large collection of bulk tumor gene expression profiles into their respective cell type–specific gene expression profiles and identify cell type–specific ligand–receptor interactions predictive of response to immune-checkpoint blockade therapy. This article is highlighted in the In This Issue feature, p. 873
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction To Compressive Sampling
Candes, E. J., & Wakin, M. B. (2008) · IEEE Signal Processing Magazine · doi:10.1109/msp.2007.914731 · Cited by 10,017
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
Visualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Drake, J. W., Charlesworth, B., Charlesworth, D., & Crow, J. F. (1998) · Genetics · doi:10.1093/genetics/148.4.1667 · Cited by 1,932
No evidence that carotenoid pigments boost either immune or antioxidant defenses in a songbird
Koch, R. E., Kavazis, A. N., Hasselquist, D., Hood, W. R., Zhang, Y., Toomey, M. B., & Hill, G. E. (2018) · Nature Communications · doi:10.1038/s41467-018-02974-x · Cited by 1,924
Phenotype molding of stromal cells in the lung tumor microenvironment
Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., Pircher, A., Van den Eynde, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0096-5 · Cited by 1,648
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Peng, J., Sun, B.-F., Chen, C.-Y., Zhou, J.-Y., Chen, Y.-S., Chen, H., Liu, L., Huang, D., Jiang, J., Cui, G.-S., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0195-y · Cited by 1,321
Thommen, D. S., Koelzer, V. H., Herzig, P., Roller, A., Trefny, M., Dimeloe, S., Kiialainen, A., Hanhart, J., Schill, C., Hess, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0057-z · Cited by 1,161
Li, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. L., Kong, S. L., Chua, C., Hon, L. K., Tan, W. S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3818 · Cited by 1,080
Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047
Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
Bassani-Sternberg, M., Bräunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13404 · Cited by 693
Revealing the vectors of cellular identity with single-cell genomics
Wagner, A., Regev, A., & Yosef, N. (2016) · Nature Biotechnology · doi:10.1038/nbt.3711 · Cited by 632
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Ward-Kavanagh, L. K., Lin, W. W., Šedý, J. R., & Ware, C. F. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.019 · Cited by 463
Overexpression of the Cytokine BAFF and Autoimmunity Risk
Steri, M., Orrù, V., Idda, M. L., Pitzalis, M., Pala, M., Zara, I., Sidore, C., Faà, V., Floris, M., Deiana, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610528 · Cited by 382
Sahraeian, S. M. E., Mohiyuddin, M., Sebra, R., Tilgner, H., Afshar, P. T., Au, K. F., Bani Asadi, N., Gerstein, M. B., Wong, W. H., Snyder, M. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00050-4 · Cited by 376
The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy
Lindeboom, R. G. H., Vermeulen, M., Lehner, B., & Supek, F. (2019) · Nature Genetics · doi:10.1038/s41588-019-0517-5 · Cited by 327
Pan-cancer deconvolution of tumour composition using DNA methylation
Chakravarthy, A., Furness, A., Joshi, K., Ghorani, E., Ford, K., Ward, M. J., King, E. V., Lechner, M., Marafioti, T., Quezada, S. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05570-1 · Cited by 327
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0342-x · Cited by 219
Spearheading future omics analyses using dyngen, a multi-modal simulator of single cells
Cannoodt, R., Saelens, W., Deconinck, L., & Saeys, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-24152-2 · Cited by 124
T-cell agonists in cancer immunotherapy
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000966 · Cited by 119
Research works printed but not linked: 63
- Paget, 1889, The distribution of secondary growths in cancer of the breast, Lancet, 133, 571, 10.1016/S0140-6736(00)49915-0 · DOI · Paper page
- Ahn, 2013, DeMix: deconvolution for mixed cancer transcriptomes using raw measured data, Bioinformatics, 29, 1865, 10.1093/bioinformatics/btt301 · DOI
- Quon, 2013, Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction, Genome Med, 5, 29, 10.1186/gm433 · DOI
- Fox, 2019, Landscape of transcriptomic interactions between breast cancer and its microenvironment, Nat Commun, 10, 3116, 10.1038/s41467-019-10929-z · DOI
- Newman, 2019, Determining cell type abundance and expression from bulk tissues with digital cytometry, Nat Biotechnol, 37, 773, 10.1038/s41587-019-0114-2 · DOI · Paper page
- Neftel, 2019, An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell, 178, 835, 10.1016/j.cell.2019.06.024 · DOI · Paper page
- Gentles, 2020, A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk, Genome Biol, 21, 107, 10.1186/s13059-020-02019-x · DOI
- Yu, 2012, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
- Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer, Nat Biotechnol, 30, 413, 10.1038/nbt.2203 · DOI · Paper page
- Aran, 2015, Systematic pan-cancer analysis of tumour purity, Nat Commun, 6, 8971, 10.1038/ncomms9971 · DOI · Paper page
- Taylor, 2018, Genomic and functional approaches to understanding cancer aneuploidy, Cancer Cell, 33, 676, 10.1016/j.ccell.2018.03.007 · DOI · Paper page
- Loeb, 1991, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res, 51, 3075
- Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 · DOI · Paper page
- Muzny, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 · DOI · Paper page
- Funkhouser, 2012, Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas a report of the association for molecular pathology, J Mol Diagn, 14, 91, 10.1016/j.jmoldx.2011.11.001 · DOI · Paper page
- Cortes-Ciriano, 2017, A molecular portrait of microsatellite instability across multiple cancers, Nat Commun, 8, 15180, 10.1038/ncomms15180 · DOI · Paper page
- Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 · DOI · Paper page
- Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, New Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
- Gurjao, 2020, Limited evidence of tumour mutational burden as a biomarker of response to immunotherapy, bioRxiv
- Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161 · DOI · Paper page
- Kalaora, 2018, Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma, Cancer Discov, 8, 1366, 10.1158/2159-8290.CD-17-1418 · DOI
- Bonneville, 2017, Landscape of microsatellite instability across 39 cancer types, JCO Precis Oncol, 1, PO.17.00073
- Litchfield, 2020, Escape from nonsense-mediated decay associates with anti-tumor immunogenicity, Nat Commun, 11, 3800, 10.1038/s41467-020-17526-5 · DOI
- McGrail, 2020, Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer, Cancer Cell, 37, 371, 10.1016/j.ccell.2020.01.011 · DOI
- Rodvold, 2017, Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells, Sci Signal, 10, eaah7177, 10.1126/scisignal.aah7177 · DOI
- Pelka, 2021, Spatially organized multicellular immune hubs in human colorectal cancer, Cell, 184, 4734, 10.1016/j.cell.2021.08.003 · DOI · Paper page
- Gros, 2014, PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors, J Clin Invest, 124, 2246, 10.1172/JCI73639 · DOI · Paper page
- Subbiah, 2020, The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians, Ann Oncol, 31, 1115, 10.1016/j.annonc.2020.07.002 · DOI · Paper page
- Strickler, 2021, Tumor mutational burden as a predictor of immunotherapy response: is more always better?, Clin Cancer Res, 27, 1236, 10.1158/1078-0432.CCR-20-3054 · DOI · Paper page
- Cancer Genome Atlas Research Network, 2013, The Cancer Genome Atlas pan-cancer analysis project, Nat Genet, 45, 1113, 10.1038/ng.2764 · DOI · Paper page
- Auslander, 2018, Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma, Nat Med, 24, 1545, 10.1038/s41591-018-0157-9 · DOI · Paper page
- Davoli, 2017, Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy, Science, 355, eaaf8399, 10.1126/science.aaf8399 · DOI · Paper page
- Steiniche, 2019, T-cell–inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC), J Clin Oncol, 37, 26, 10.1200/JCO.2019.37.4_suppl.26 · doi:10.1200/jco.2019.37.4_suppl.26
- Ock, 2017, Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers, Nat Commun, 8, 1050, 10.1038/s41467-017-01018-0 · DOI · Paper page
- Perez-Guijarro, 2020, Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy, Nat Med, 26, 781, 10.1038/s41591-020-0818-3 · DOI · Paper page
- Billadeau, 2002, ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest, 109, 161, 10.1172/JCI0214843 · DOI · Paper page
- Staub, 2004, Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome, Cell Signal, 16, 435, 10.1016/j.cellsig.2003.08.013 · DOI
- Varin, 2010, B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF, Autoimmun Rev, 9, 604, 10.1016/j.autrev.2010.05.006 · DOI
- Murphy, 2016, Janeway's immunobiology, 10.1201/9781315533247 · DOI · Paper page
- Campbell, 2011, Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations, Immunology, 132, 315, 10.1111/j.1365-2567.2010.03398.x · DOI · Paper page
- Pende, 2019, Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation, Front Immunol, 10, 1179, 10.3389/fimmu.2019.01179 · DOI · Paper page
- Gonçalves, 2018, CD6, a rheostat-type signalosome that tunes T cell activation, Front Immunol, 9, 2994, 10.3389/fimmu.2018.02994 · DOI
- Chen, 2014, The function of BAFF on T helper cells in autoimmunity, Cytokine Growth Factor Rev, 25, 301, 10.1016/j.cytogfr.2013.12.011 · DOI
- Chen, 2015, Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model, Cancer Immunol Res, 3, 149, 10.1158/2326-6066.CIR-14-0118 · DOI · Paper page
- Ma, 2019, A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity, Cancer Immunol Res, 7, 428, 10.1158/2326-6066.CIR-18-0061 · DOI · Paper page
- Barber, 2014, Costimulation of effector CD8+ T cells: which receptor is optimal for immunotherapy?, MOJ Immunol, 1, 00011, 10.15406/moji.2014.01.00011 · DOI
- Melero, 2013, Agonist antibodies to TNFR molecules that costimulate T and NK cells, Clin Cancer Res, 19, 1044, 10.1158/1078-0432.CCR-12-2065 · DOI · Paper page
- Philipson, 2020, 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-kappaB signaling, Sci Signal, 13, eaay8248, 10.1126/scisignal.aay8248 · DOI · Paper page
- Siu, 2017, Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors, J Clin Oncol, 35, 104, 10.1200/JCO.2017.35.15_suppl.104 · DOI · Paper page
- Tolcher, 2017, Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with Pembrolizumab (MK-3475) in patients with advanced solid tumors, Clin Cancer Res, 23, 5349, 10.1158/1078-0432.CCR-17-1243 · DOI · Paper page
- Cohen, 2019, A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors, J Immunother Cancer, 7, 342, 10.1186/s40425-019-0815-6 · DOI
- Wu, 2018, Limitations of alignment-free tools in total RNA-seq quantification, BMC Genomics, 19, 510, 10.1186/s12864-018-4869-5 · DOI · Paper page
- Everaert, 2017, Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data, Sci Rep, 7, 1559, 10.1038/s41598-017-01617-3 · DOI · Paper page
- Teng, 2016, A benchmark for RNA-seq quantification pipelines, Genome Biol, 17, 74, 10.1186/s13059-016-0940-1 · DOI · Paper page
- Robert, 2015, Errors in RNA-seq quantification affect genes of relevance to human disease, Genome Biol, 16, 177, 10.1186/s13059-015-0734-x · DOI · Paper page
- Chu, 2020, Bayesian inference of cell composition and gene expression reveals tumor-microenvironment interactions, bioRxiv
- Bray, 2016, Near-optimal probabilistic RNA-seq quantification, Nat Biotechnol, 34, 525, 10.1038/nbt.3519 · DOI · Paper page
- Harrow, 2012, GENCODE: the reference human genome annotation for The ENCODE Project, Genome Res, 22, 1760, 10.1101/gr.135350.111 · DOI · Paper page
- Robinson, 2010, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics, 26, 139, 10.1093/bioinformatics/btp616 · DOI · Paper page
- Robinson, 2010, A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, 11, R25, 10.1186/gb-2010-11-3-r25 · DOI · Paper page
- Ma, 2019, Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer, Cancer Cell, 36, 418, 10.1016/j.ccell.2019.08.007 · DOI · Paper page
- Karaayvaz, 2018, Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq, Nat Commun, 9, 3588, 10.1038/s41467-018-06052-0 · DOI · Paper page
- Bird, 2002, DNA methylation patterns and epigenetic memory, Genes Dev, 16, 6, 10.1101/gad.947102 · DOI · Paper page
Cited by
Swanson, K., Wu, E., Zhang, A., Alizadeh, A. A., & Zou, J. (2023) · Cell · doi:10.1016/j.cell.2023.01.035 · Cited by 597
“CIBERSORTx and CODEFACS have expanded CIBERSORT to deconvolve bulk RNA using nu-support vector regression (n-SVR) analysis and achieve cell-type-specific gene expression without single-cell data.(78,79) While most deconvolution efforts have thus far focused on bulk cellular tissue sources such as tumor specimens, ML d…”
MethodMechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Big data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells
Bendre, S. V., Wang, Y., Hajyousif, B., K C, R., Bhogale, S. G., Pradeep, D., Krawczynska, N., Schane, C. P., Weisser, E., Singh, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.adx5490 · Cited by 8
Self-citation
Metadata
- Authors
- Wang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E.
- Venue
- Cancer Discovery
- Published
- 2022-01-04
- Volume
- 12
- Issue
- 4
- Pages
- 1088-1105
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4206676821
- Cited by
- 55
- References
- 37
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- HHS | National Institutes of Health (1ZIABC011802-02)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.